About ImPact Biotech
ImPact Biotech is a company based in Ness Ziona (Israel) founded in 2022. ImPact Biotech offers products and services including Padeliporfin VTP. ImPact Biotech operates in a competitive market with competitors including Insulet, Lyra Therapeutics, Credence MedSystems, TriSalus Life Sciences and Sixfold Bioscience, among others.
- Headquarter Ness Ziona, Israel
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website impactbiotech.com
Products & Services of ImPact Biotech
ImPact Biotech offers a comprehensive portfolio of products and services, including Padeliporfin VTP.
Platform for targeted photodynamic therapy treating solid tumors effectively.
People of ImPact Biotech
1 people are tracked at ImPact Biotech (1 in leadership).
| Name | Role | Group |
|---|---|---|
Barak Palatchi | CEO | Leadership |
Complete people profiles for ImPact Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of ImPact Biotech
ImPact Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, Credence MedSystems, TriSalus Life Sciences and Sixfold Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| lyratherapeutics.com | 2005 | Watertown, United States | $127.61M | 75 | Small molecule therapeutics for ENT diseases are developed. | |
| credencemed.com | 2011 | Menlo Park, United States | $112.61M | – | Developer of smart devices for drug delivery | |
| trisaluslifesci.com | 2009 | Westminster, United States | $83.37M | 100 | Developer of drug delivery devices to treat cancers | |
| sixfold.bio | 2017 | London, United Kingdom | $4.59M | 16 | Oligonucleotide delivery systems are developed for targeted gene therapy. | |
| foreseepharma.com | 2011 | Taipei, Taiwan | $32.5M | – | Injectables and NCEs for cancer and chronic diseases are developed. | |
| genprex.com | 2009 | Austin, United States | $3.11M | 28 | Therapeutics for molecular-level cancer treatment are developed. | |
| cellectar.com | 2002 | Florham Park, United States | – | 15 | Phospholipid drug conjugates for cancer treatment are developed. | |
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| renovorx.com | 2009 | Los Altos, United States | $10.91M | 6 | Developing endovascular catheters for targeted delivery of IV fluids to peripheral organs |
Detailed competitors of ImPact Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Impact Biotech
Complete news archive for ImPact Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ImPact Biotech
10 companies that operate in the same segment as ImPact Biotech (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ImPact Biotech
ImPact Biotech was founded in 2022.
ImPact Biotech is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Barak Palatchi is the current CEO of ImPact Biotech.
Developer of a drug delivery platform for the treatment of solid tumors. It provides Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, which involves injecting a drug called Padeliporfin that a non-thermal laser light activates. It aids in tumour blood supply obstruction, cell death, and immune system activation to kill cancer cells.
ImPact Biotech's top competitors include Insulet, Lyra Therapeutics and TriSalus Life Sciences.
ImPact Biotech offers Padeliporfin VTP.